aetna®

MEDICARE FORM

Cinqair® (reslizumab) Medication Precertification Request

(All fields must be completed and legible for precertification review.)

Virginia (HMO D-SNP)
FAX: 1-833-280-5224
PHONE: 1-855-463-0933

For other lines of business:
Please use other form

Note: Cinqair is non-preferred. The preferred products are Nucala and Xolair.

Please indicate: ☐ Start of treatment: Start date ____/____/____
☐ Continuation of therapy: Date of last treatment ____/____/____

Precertification Requested By: _____ Phone: _____ Fax: _____

A. PATIENT INFORMATION

First Name:	Last Name:		
Address:	City:	State:	ZIP:
Home Phone:	Work Phone:	Cell Phone:	
DOB:	Allergies:	Email:	

Current Weight: _____ lbs or _____ kgs Height: _____ inches or _____ cms

B. INSURANCE INFORMATION

Aetna Member ID #: _____
Group #: _____
Insured: _____

Does patient have other coverage? ☐ Yes ☐ No
If yes, provide ID#: _____ Carrier Name: _____
Insured: _____

Medicare: ☐ Yes ☐ No If yes, provide ID #: _____ **Medicaid**: ☐ Yes ☐ No If yes, provide ID #: _____

C. PRESCRIBER INFORMATION

First Name:		Last Name: *(Check One):* ☐ M.D. ☐ D.O. ☐ N.P. ☐ P.A.			
Address:		City:	State:	ZIP:	
Phone:	Fax:	St Lic #:	NPI #:	DEA #:	UPIN:
Provider Email:		Office Contact Name:		Phone:	

Specialty *(Check one):* ☐ **Pulmonologist** ☐ **Allergist** ☐ **Other**: _____

D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

Place of Administration:
☐ Self-administered ☐ Physician's Office
☐ Outpatient Infusion Center Phone: _____
Center Name: _____
☐ Home Infusion Center Phone: _____
Agency Name: _____
☐ Administration code(s) (CPT): _____
Address: _____
City: _____ State: _____ ZIP: _____
Phone: _____ Fax: _____
TIN: _____ PIN: _____
NPI: _____

Dispensing Provider/Pharmacy: *Patient Selected choice*
☐ Physician's Office ☐ Retail Pharmacy
☐ Specialty Pharmacy ☐ Other _____
Name: _____
Address: _____
City: _____ State: _____ ZIP: _____
Phone: _____ Fax: _____
TIN: _____ PIN: _____
NPI: _____

E. PRODUCT INFORMATION

Request is for: Cinqair (reslizumab) Dose: _____ **Frequency:** _____

F. DIAGNOSIS INFORMATION – Please indicate primary ICD Code and specify any other where applicable.

Primary ICD Code: _____ **Secondary ICD Code:** _____ **Other ICD Code:** _____

G. CLINICAL INFORMATION – Required clinical information must be completed in its entirety for all precertification requests.

For All Requests (clinical documentation required):

Note: Cinqair is non-preferred. The preferred products are Nucala, and Xolair.

☐ Yes ☐ No Has the patient had prior therapy with Cinqair within the last 365 days?

☐ Yes ☐ No Has the patient had a trial and failure, intolerance, or contraindication to any of the following? (select all that apply)
☐ Nucala (mepolizumab) ☐ Xolair (omalizumab)

Please explain if there are any other medical reason(s) that the patient cannot use any of the following preferred products when indicated for the patient's diagnosis? (select all that apply)
☐ Nucala (mepolizumab) ☐ Xolair (omalizumab)

_____

Continued on next page

aetna®

MEDICARE FORM

Cinqair® (reslizumab) Medication Precertification Request

(All fields must be completed and legible for precertification review.)

Virginia (HMO D-SNP)
FAX: 1-833-280-5224
PHONE: 1-855-463-0933

For other lines of business:
Please use other form

Note: Cinqair is non-preferred. The preferred products are Nucala and Xolair.

Patient First Name	Patient Last Name	Patient Phone	Patient DOB

G. CLINICAL INFORMATION *(continued)* – Required clinical information must be completed in its entirety for all precertification requests.

☐ Yes ☐ No Is this infusion request in an outpatient hospital setting?

→ ☐ Yes ☐ No Has the patient experienced an adverse event with the requested product that has not responded to conventional interventions (e.g., acetaminophen, steroids, diphenhydramine, fluids, other pre-medications or slowing of infusion rate) or a severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, or seizures) during or immediately after an infusion?

☐ Yes ☐ No Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting?

☐ Yes ☐ No Does the patient have significant behavioral issues and/or physical or cognitive impairment that would impact the safety of the infusion therapy AND the patient does not have access to a caregiver?

→ Please provide a description of the behavioral issue or impairment: _____

☐ Yes ☐ No Is the patient medically unstable which may include respiratory, cardiovascular, or renal conditions that may limit the member's ability to tolerate a large volume or load or predispose the member to a severe adverse event that cannot be managed in an alternate setting without appropriate medical personnel and equipment?

→ Please provide a description of the condition:
- ☐ Cardiovascular: _____
- ☐ Respiratory: _____
- ☐ Renal: _____
- ☐ Other: _____

☐ Yes ☐ No Does the patient have a documented diagnosis of asthma?

☐ Yes ☐ No Will the patient receive Cinqair as monotherapy (i.e., without any other asthma medications such as inhaled corticosteroids)?

☐ Yes ☐ No Will the patient be taking Cinqair concomitantly with other biologics indicated for asthma (e.g., Dupixent, Fasenra, Nucala, Xolair)?

For Initial Requests:

Please indicate the patient's baseline (e.g., before significant oral steroid use) blood eosinophil count in cells per microliter: _____

Please indicate the preferred alternatives for asthma that have been ineffective, not tolerated, or are contraindicated: ☐ Fasenra ☐ Nucala ☐ Xolair

☐ Yes ☐ No Is the patient dependent on systemic corticosteroids?

☐ Yes ☐ No Does the patient have inadequate asthma control (e.g., hospitalization or emergency medical care visit within the past year) despite current treatment with both of the following medications: inhaled corticosteroid and additional controller (long acting beta-2 agonist, leukotriene modifier, or sustained-release theophylline) at optimized doses?

For Continuation Requests:

☐ Yes ☐ No Is the patient currently receiving Cinqair through samples or a manufacturer's patient assistance program? (Sampling of Cinqair does not guarantee coverage under the provisions of the pharmacy benefit)

☐ Yes ☐ No Has asthma control improved on Cinqair treatment as demonstrated by a reduction in the frequency and/or severity of symptoms and exacerbations?

H. ACKNOWLEDGEMENT

Request Completed By *(Signature Required):* _____ **Date:** ____/____/____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.